LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Collaboration to Undertake HIV Resistance Testing in Africa

By LabMedica International staff writers
Posted on 06 Aug 2012
Print article
Sequencing-based diagnostics for human immunodeficiency virus (HIV)-infected individuals will be carried out in Africa in order to determine resistance to antiretroviral drugs.

Life Technologies Corp. (Carlsbad, CA, USA) is collaborating with the Southern African Treatment and Resistance Network (SATuRN) to develop a simple-to-answer solution for antiretroviral (ARV) drug resistance testing, which is being made available to African partners at a reasonable cost per test. The test can be run on Life's Applied Biosystems line of Sanger sequencing instruments, which are broadly installed in African hospitals and HIV-testing centers.

Antiretroviral (ARV) drugs for HIV treatment are becoming increasingly available in the developing world but resistance to these drugs develops in many HIV-infected individuals. Resistance can be monitored by genetic sequencing of two viral genes, but current costs have made routine use prohibitive in most African countries.

The methods developed as part of this collaboration have the potential to become the most accurate and cost-effective methods for the diagnosis of resistance pathogens in Africa and the referral of patients for appropriate care. The price of DNA/RNA genotyping is rapidly decreasing as technology evolves rapidly, and the software applications to be used and further developed are all open source and available in Africa.

Additional collaborators on the test development include the Stanford HIV Drug Resistance Database).

"We have trained 1,315 physicians and medical personnel on the interpretation of HIV drug resistance in southern Africa. The region has more than 2 million patients on ARV treatment, and we believe that now is the time for the use of genotyping technology to fight the battle against drug resistance," said Dr. Tulio de Oliveira, director of SATuRN and senior researcher at Wellcome Trust-Africa Centre. "This partnership with LIFE will allow more laboratories to use genotyping techniques, and large surveys on drug resistance to be produced to inform national department of health and policy makers in the region."

SATuRN is a consortium of virologists, clinicians, epidemiologists, bioinformaticians, policy makers, public health specialists, and social scientists working on HIV treatment and care in southern Africa. SATuRN has developed an approach to virological failure clinical management that ensures the delivery of drug resistance genotyping and clinical management to remote clinics without them needing elaborate computer systems or infectious disease specialists on site.

By applying telemedicine and off site laboratories, specialists and physicians from medical centers across the world can review cases, including clinical and resistance data, and give feedback and advice to the clinician managing the patient at the primary clinic.

Life Technologies Corp. is a global biotechnology company. It has more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety, and animal health.

Related Links:
Life Technologies Corp.
Saturn
Stanford HIV Drug Resistance Database

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more